Gisli Jenkins completed his medical training at University of Southampton before undertaking postgraduate training in Respiratory Medicine in London.
During this time he undertook basic scientific training funded by an ARC Fellowship and obtained a PhD in Biochemistry from UCL before doing postdoctoral studies at UCSF as part of an ARC Clinician Scientist Fellowship. Currently Dr Jenkins is an Associate Professor and Honorary Consultant at the University of Nottingham. Dr Jenkins’ heads a laboratory focused on Pulmonary Fibrosis, and is also the Clinical Lead for the Nottingham Interstitial Lung Diseases Unit.
Dr Jenkins’ research focuses on the mechanism by which injury leads to scarring in the lung. Lung scarring is the central process leading to disability and death in people with Idiopathic Pulmonary Fibrosis, and also occurs in diseases such as chronic asthma where it promotes airway remodelling and impaired lung function.
The major focus of the laboratory is on:
a) mechanistic studies understanding the molecular and cellular processes the lead to the development of pulmonary fibrosis
b) modelling studies that determine the importance of these molecular and cellular pathways in the lung
c) translational studies developing the molecules involved in this pathway for use as biomarkers and therapeutics in people with IPF.
Dr Jenkins’ research group has received funding from Academic organisations including the Wellcome Trust, the Medical Research Council, Arthritis Research UK and Asthma UK as well as Industrial contracts with GlaxoSmithKline and Novartis.